Hallux Subungual Gel (HSG)

About Hallux

Hallux Inc. is developing a physician-administered topical gel, HSG, for onychomycosis, utilizing a unique subungual delivery method to bypass the nail plate and deliver terbinafine directly to the infected nail bed. The company is nearing completion of a Phase 2a study and positions its product as a potential paradigm shift, combining the efficacy of oral antifungals with the safety profile of topicals. With a seasoned leadership team and a focus on a large, underserved market, Hallux seeks to address significant limitations of current treatments, including poor efficacy, long treatment durations, and systemic side effects.

Therapeutic Areas